Fig 2: Expression levels of PDGFRs and key factors of the Notch pathway by immunohistochemical staining. (A) The expression levels of PDGFRs in ovarian cancer tissues from patients. Magnification, ×200. *P<0.05. (B) The expression levels of key Notch pathway factors in the xenograft tumours derived from anisomycin-treated or DMSO-treated ovarian cancer stem cells. Magnification, ×200. *P<0.05 and **P<0.01 (n=4). PDGFR, platelet-derived growth factor receptor; DLL1, d-like canonical Notch ligand 1; HES1, hes family bHLH transcription factor 1; RBPJ, recombination signal binding protein for immunoglobulin ? J region.

Fig 3: miR-421 enhances the inhibitory effect of anisomycin on HuOCSCs. (A) MTT results showed that overexpression of miR-421 and treatment with anisomycin resulted in more severe proliferation inhibition of HuOCSCs, than either treatment alone. **P<0.01 vs. DMSO group (n=4). (B) Quantitative PCR results showed that overexpression of miR-421 and treatment with anisomycin decreased the expression of lncRNA-Meg3, PDGFRA, Notch1, HES1 and RBPJ. **P<0.01 vs. DMSO group (n=4). (C) Schematic of the proposed molecular mechanism of anisomycin inhibition of the activity and angiogenesis of ovarian cancer cells, by attenuating the molecular sponge effect in the lncRNA-Meg3/miR-421/PDGFRA axis. miR, microRNA; HuOCSCs, human ovarian cancer stem cells; lncRNA, long non-coding RNA; Meg3, maternally expressed 3; PDGFRA, platelet derived growth factor receptor a; HES1, hes family bHLH transcription factor 1; RBPJ, recombination signal binding protein for immunoglobulin ? J region; mut, mutant.

Fig 4: Anisomycin affects the expression of PDGFRs and Notch pathway components in ovarian cancer stem cells. (A) mRNA expression levels of key factors of the Notch pathway, PDGFRA and PDGFRB in ovarian cancer tissues with more and less CD44+/CD133+ HuOCSCs. **P<0.01. (B) mRNA expression levels of key factors of the Notch pathway, PDGFRA and PDGFRB in CD44+/CD133+ HuOCSCs following anisomycin treatment. **P<0.01 vs. non-treated (n=4). (C) Western blotting results from the experimental groups of panel A. (D) Western blotting results from the experimental groups of panel B. PDGFR, platelet-derived growth factor receptor; HuOCSCs, human ovarian cancer stem cells; DLL1, d-like canonical Notch ligand 1; HES1, hes family bHLH transcription factor 1; RBPJ, recombination signal binding protein for immunoglobulin ? J region.

Fig 5: Beta-elemene modulates the expression of several regulators and signal events in NSCLC cells, dependent on C3orf21 expression. The indicated NSCLC cells were treated with, or without, beta-elemene for 24 h and the relative levels of MMP-2 (A), MMP-9 (B), VEGF (C), PTEN (D) Cyclin (E), C-Myc (F), and COX2 (G) in the indicated NSCLC cells were quantified by RT-PCR. Data are present as mean ± SD of each group from at least three biological experiments. **P < 0.01 and ***P < 0.001 vs. the control.